Maria F Gomez-Ardila - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

European Heart Journal Open|April 20, 2026

Moderate-dose doxorubicin does not affect right ventricular size or function parameters in lymphoma patients-a single-center studyEduardo Brenner-Muslera, Maria F Gomez-Ardila, Eduardo Tellez-Garcia, et al.

Cardio-Oncology (London, England)|June 13, 2025

Assessing double product derived from stress echocardiography as a prognostic indicator of major adverse cardiac events in patients with breast cancer treated with radiotherapyJuan Manuel Garzon-Dangond, Maria F Gomez Ardila, Eduardo Tellez Garcia, et al.

Cardio-Oncology (London, England)|December 21, 2024

Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignanciesAndres E Daryanani, Muhannad A Abbasi, Maria F Gomez Ardila, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

European Heart Journal Open|April 20, 2026

Moderate-dose doxorubicin does not affect right ventricular size or function parameters in lymphoma patients-a single-center studyEduardo Brenner-Muslera, Maria F Gomez-Ardila, Eduardo Tellez-Garcia, et al.

Cardio-Oncology (London, England)|June 13, 2025

Assessing double product derived from stress echocardiography as a prognostic indicator of major adverse cardiac events in patients with breast cancer treated with radiotherapyJuan Manuel Garzon-Dangond, Maria F Gomez Ardila, Eduardo Tellez Garcia, et al.

Cardio-Oncology (London, England)|December 21, 2024

Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignanciesAndres E Daryanani, Muhannad A Abbasi, Maria F Gomez Ardila, et al.

Pageof 1